Cullinan Oncology
Cambridge
Massachusetts
United States
Website: https://www.cullinanoncology.com/
Email: info@cullinanoncology.com
97 articles about Cullinan Oncology
-
Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417
6/23/2022
Cullinan Oncology, Inc. (Cullinan Oncology) (Nasdaq: CGEM) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced the completion of its agreement with Taiho Pharmaceutical Co., Ltd. (Taiho) signed in May 2022.
-
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 01, 2022
6/1/2022
Cullinan Oncology, Inc. announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 174,000 shares of its common stock to four employees outside Cullinan Oncology, Inc’s 2021 Stock Option and Incentive Plan.
-
Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting
5/31/2022
Updated data from Phase 1/2a study show median duration of response greater than 21 months and median progression-free survival of 12 months at 100 mg BID dose.
-
Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting
5/26/2022
Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that it will host an investor and analyst briefing during the 2022 American Society of Clinical Oncology (ASCO) Annual meeting.
-
Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference
5/19/2022
Cullinan Oncology, Inc. announced that its Chief Financial Officer, Jeff Trigilio, will present at the H.C. Wainwright Global Investment Conference, being held May 23-25 in Miami, FL and virtually.
-
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results
5/16/2022
Cullinan Oncology, Inc. reported on recent and upcoming business highlights and announced its financial results for the first quarter ended March 31, 2022.
-
Cullinan and Taiho announced that Taiho was acquiring Cullinan Pearl and will co-develop and co-commercialize their non-small cell lung cancer drug.
-
Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl
5/12/2022
Cullinan Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced an agreement through which Taiho will acquire Cullinan Pearl Corp. and co-develop and co-commercialize Cullinan Oncology’s lead program, CLN-081/TAS6417, an orally available, differentiated, irreversible EGFR inhibitor that selectively targets cells expressing EGFR exon 20 insertion mutations while sparing cells expressing wild-type EGFR.
-
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 02, 2022
5/2/2022
Cullinan Oncology, Inc. announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 207,000 shares of its common stock to two employees outside Cullinan Oncology, Inc’s 2021 Stock Option and Incentive Plan.
-
Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting
4/27/2022
Cullinan Oncology, Inc. announced the presentation of updated clinical research highlighting the therapeutic potential of its lead asset, CLN-081, in patients with epidermal growth factor receptor exon 20 insertion mutation positive non-small cell lung cancer at the 2022 American Society of Clinical Oncology Annual Meeting taking place in Chicago from June 3-7, 2022.
-
Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences in April 2022
4/5/2022
Cullinan Oncology, Inc. a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, announced that its management team will participate in the following virtual conferences in April.
-
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/4/2022
Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 279,100 shares of its common stock to four employees outside Cullinan Oncology, Inc’s 2021 Stock Option and Incentive Plan.
-
Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients
3/28/2022
Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan), today announced clinical and regulatory updates on its lead program, CLN-081.
-
Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022
3/17/2022
Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, will provide a regulatory update on CLN-081 during a webinar being held Monday, March 28, 2022, at 4:30 p.m. ET.
-
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
3/17/2022
Cullinan Oncology, Inc. today reported on recent and upcoming business highlights and announced its financial results for the fourth quarter and full year ended December 31, 2021.
-
Cullinan Oncology to Present at the Barclays Global Healthcare Conference - Mar 09, 2022
3/9/2022
Cullinan Oncology, Inc., a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, announced that it will be participating in the Barclays Healthcare Conference, being held in Miami, FL, March 15-17, 2022.
-
Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022
3/8/2022
Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, today announced that it will present data across five distinct immuno-oncology programs at the American Association for Cancer Research (AACR) Annual Meeting taking place April 8-13, 2022 in New Orleans.
-
BioSpace Movers & Shakers, March 4
3/4/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Cullinan Oncology Expands Leadership Team and Board of Directors with Appointments of Jeffrey Jones, M.D., MPH, MBA to Chief Medical Officer and Anne-Marie Martin Ph.D. to Board of Directors
2/28/2022
Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that Jeffrey (Jeff) Jones, M.D., MPH, MBA will join the company as Chief Medical Officer and Anne-Marie (Annie) Martin, Ph.D., has been appointed to the Company’s Board of Directors.
-
Cullinan Oncology to Present at SVB Leerink’s 11th Annual Global Healthcare Conference
2/7/2022
Cullinan Oncology, Inc. announced that it will be participating in SVB Leerink’s 11th Annual Global Healthcare Conference, being held virtually February 14-18, 2022.